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This study evaluated the subchronic toxicity of selected halomethanes which are drinking
water contaminants. The compounds studied were trichloromethane, bromodichloromethane,
dibromochloromethane and tribromomethane. Subchronic 14-day gavage studies were performed
with the use ofdoses encompassing one-tenth the LD50 forthe compounds. A 90-day gavage study
of one of the compounds, trichloromethane, was also done. Parameters observed included body
and organ weights, histopathology, hematology, clinical chemistries, and hepatic microsomal
enzyme activities. Toxicity to the humoral immune system was assessed by measuring the
number of splenic IgM antibody-forming cells and the serum antibody level to sheep erythro-
cytes. Cell-mediated immunity was evaluated by measuring the delayed type hypersensitivity
response and popliteal lymph node proliferation response to sheep red blood cells. The functional
activity ofthe reticuloendothelial system, as measured by the vascular clearance rate and tissue
uptake of 51Cr sheep red blood cells was also determined.
The major effects of the halomethanes were increased liver weights, elevations of SGPT and
SGOT, decreased spleen weights and a decrease in the number of splenic IgM antibody-forming
cells. The humoral immune system appeared to be an indicator ofhalomethane toxicity. There is
evidence that subchronic 14-day exposure may be of greater value than long-term studies in
determining the toxicity of these compounds.
Introduction
In a study involving 80 U.S. cities, trichloro-
methane, bromodichloromethane, dibromochloro-
methane, or tribromomethane were found in all
finished drinking water supplies at levels up to 311
,ug/l. (1). Finished water supplies for which surface
waterwastheoriginalsourceandinwhichdisinfection
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was accomplished by chlorination contained the
highestlevelsofhalomethanes. Totaltrihalomethane
concentrations were, for the most part, related to
the chlorination of raw water containing organic
material.
At present the effects ofchronic low level inges-
tion of trihalomethanes in drinking water are not
known, although it has been suggested by Cantor
(2) that an association between bladder cancer
mortality rates and trihalomethane levels in drink-
ing water exists. To understand the toxicology of
the trihalomethanes better, this study investigated
their effects upon the immune system in addition to
the usual toxicological parameters. We performed118
subehronic 14-day studies in male and female mice
with the selected trihalomethanes, as well as a
90-day study with trichloromethane, to determine
if effects seen with short-term exposure would
increase ordiminish with long-term administration.
It was found that the trihalomethanes affected
primarily the liver and the spleen, with resulting
implications for the immune system, and that
certain effects diminished withlong-term exposure.
Materials and Methods
CD-1 male and female mice were purchased from
Charles River Breeding Laboratories, Wilmington,
Massachusetts, and housed four perplastic shoebox
cage with sawdust bedding and free access to
Agway Lab Chow and deionized drinking water.
The mice were individually tagged by earpunching
and quarantined for one week prior to experimen-
tation. The room was maintained at 21-240C and a
relative humidity of 40-60%. The light-dark cycle
was set on 12 hr intervals.
Trichloromethane (Fisher Scientific Co., Rich-
mond, Va. 23230; lot #790372), tribromomethane
(Aldrich Chemical Co., Milwaukee, Wisc. 53233; lot
#13294-2),bromodichloromethane(PflatzandBauer
Inc., Stamford, Conn. 06902; lot #320355), and
dibromochloromethane (Columbia Organic Chemi-
calCo., Columbia, S.C.; lot #020580) were obtained
from commercial sources. Solutions for gavage
were prepared fresh daily in 10% Emulphor in
deionized water, and appropriate concentrations
were administered in a volume of 0.01 ml/g body
weight to deliver the desired dose. The dose levels
chosen for these studies were 50, 125 and 250
mg/kg/day for 14 days. A 90-day subehronic study
was also done for one of the chemicals, trichloro-
methane, using the same dosages.
Animals were anesthetized with chloroform and
blood was collected immediately by cardiac punc-
ture. Gross pathological examinations were per-
formed on all mice. The organs (brain, liver, lungs,
spleen, thymus, kidneys, and testes) were then
removed, trimmed, and weighed. Material for his-
tologic analysis (kidney, liver, spleen) was fixed in
10% buffered formalin, infiltrated and embedded in
paraffin, sectioned at 6 microns, and stained with
hematoxylin and eosin. Livers and spleens not
destined for histologic study were used in addi-
tional procedures.
Blood samples for hematological study were
taken in 3.2% sodium citrate. Leukocyte, erythro-
cyte and platelet counts were performed on a
Coulter Counter, Model ZBI. Hematocrits were
performed with microhematocrit equipment and
hemoglobins determined as cyanomethemoglobin.
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Leukocyte differentials were evaluated using the
standardWright's-Giemsastainingprocedure. Bone
marrow cells were flushed from the femur in
a-MEM with 5% fetal calf serum and enumerated
on the Coulter Counter.
The plasma from the blood samples was assayed
forextrinsicactivitybyprothrombintime. Reagents
forthis assay were obtained from General Diagnos-
tics. Fibrinogen levels were determined by the
kinetic method, usingreagents from Dade Diagnos-
tics Inc., Miami, Florida.
For clinical chemistry studies, additional blood
samples were drawn by cardiac puncture from
animals used forstudies onhumoralimmunity, then
allowed to clot. The sera from these samples were
loadedontoanAbbottBichromaticAnalyzer, Model
100, andprocessedaccordingtoproceduresdescribed
in the Operator's Manual.
Livers for microsomal assay were removed,
weighed, rinsed, and homogenized at 4°C in four
volumes of 0.15M potassium chloride containing
0.1M potassium phosphate buffer, pH 7.4. The
homogenate was centrifuged at 9000g for 20 min
and the supernatant recentrifuged at 100,000g for 1
hr in a Beckman Model L5-50 ultracentrifuge. The
microsomes in the pellet were resuspended in
0.05M potassium phosphate buffer, pH 7.4 (0.5 g of
liver/ml), and aliquots were taken for immediate
study.
Microsomal protein was assayed by the method
of Lowry et al. (3). The cytochrome P-450 content
wasdetermined fromthereducedCO versusreduced
difference spectrum, using an extinction coefficient
of 91 cm-'mm71 (4). Aminopyrine N-demethylase
activity was determined by measuring formalde-
hyde production by the Nash reaction as described
by Cochin and Axelrod (5). Aniline hydroxylase
activity was measured as p-aminophenol pro-
duction (6).
The primary IgM response to sheep erythrocytes
(sRBC), a measure of humoral immunity, was
estimated by the hemolytic plaque assay of Jerne
and Nordin (7) as modified by Cunningham and
Szenberg (8). Mice were immunized with 4 x 108
sRBC by IP injection 4 days prior to sacrifice.
Spleen cell suspensions were prepared in RPMI
1640 culture medium using stainless steel mesh
screens and adjusted to a cell concentration of
106/ml for assay of antibody-forming cells (AFC).
As a complement to the plaque assay, the plasma
antibody titer was measured by the hemagglutina-
tion technique. Seven days after IP injection of 109
sRBC, blood was collected by cardiac puncture
from chloroform-anesthetized animals into 3.2%
sodium citrate. After centrifugation, the plasma
was heat inactivated, and serial (1:1) dilutions were
made in phosphate-buffered saline. To each of theTOXICOLOGY OF DRINKING WATER CONTAMINANTS
dilutions in a microtiter well, an equal volume of a
0.5% suspension ofsRBC was added. After incuba-
tion for 2 hr at 37°C, the plates were observed on a
magnifying mirror for agglutination of the sRBC.
The antibody titers were expressed as log2 of the
reciprocal of the first dilution with no visible
agglutination.
Cell-mediated immunity was evaluated by meas-
uring the delayed type hypersensitivity (DTH)
response to sRBC. This is a modification of the
methods of Lagrange et al. (9) and Paranjpe and
Boone (10). Sensitization was accomplished by
injecting 108 sRBC in a volume of 0.02 ml into the
leftfootpad (LFP). Fourdays followingsensitization
the mice were challenged in the LFP with 4 x 10
sRBC in a volume of 0.04 ml. At 17 hr following
challenge, the mice were injected intravenously
with 0.3 ml of 125I-human serum albumin (HSA)
(80,000 cpm/0.1 ml). Two hours later, themice were
sacrificed by cervical dislocation, and both hind feet
were removed at the ankle joint and radioassayed
in a gamma counter. The right footpad (RFP)
served as an unchallenged control for background
125I-HSA. A group of mice which was not sensi-
tized, but was challenged as above, acted as unsen-
sitized controls to determine nonspecific swelling.
Results are expressed as a stimulation index (SI),
which is calculated as follows:
SI = cpm LFPsensitized\ -[cpm LFP unsensitized
(cpm RFP sensitized L-\cpm RFP unsensitiz)ed]
Popliteal lymph node proliferation in response to
sRBC was determined to further evaluate cellular
immunity. Mice were sensitized 4 days prior to the
last day ofgavage by injection of 1 x 108 sRBC in
0.02 ml of Alsever's solution into the left hind
footpad (LFP). One group of control mice was
injected with saline to measure nonspecific stimula-
tion. Four days later, the animals were challenged
by injecting 4 x 108 sRBC in 0.04 ml Alsever's
solution into the LFP. At 1.5 hr after challenge, the
mice were given an IP injection of0.2 ml FUdR (8
x 10M). An IV injection of 2.0 ,uCi 1251-labeled
iododeoxyuridine in 0.2 ml saline was administered
30 min later. The mice were sacrificed 20 hr after
labeling, andthepopliteallymphnodeswereremoved
and counted in a gamma counter. The stimulation
index was calculated as shown below:
( SENSITIZED UNSENSITIZED
SI = cpm left popliteal node )- cpm left popliteal node
cpm right popliteal node/ -\cpm right popliteal node/
Several particles for measuring the phagocytic
activity of the fixed macrophage system had been
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compared previously (11). For these studies we
used sRBC. Freshly-drawn sRBC (5 x 109cells/ml)
were radiolabeled with 51sodium chromate in a 37°C
shaker bath with 1 mCi/5 ml cells for 30 min. After
chromation, the sRBC were washed with Alsever's
solution until the supernatant was virtually radio-
activity free. Unlabeled sRBC (5 x 109 ml) were
added to the labeled cells until the hematocrit was
10%. The resulting cpm's were approximately
200,000/0.1 ml. The sRBC were refrigerated and
used the following day. Before use, the cells were
washed to remove any free chromium released
overnight.
Mice used for evaluation of RES activity were
weighed and placed in shoebox cages maintained at
21°C. At zero time, 0.1 ml of labeled particle/10 g
body weight was injected intravenously. Blood
samples (10 ,ul) weretakenfromthetip ofthe tail at
2, 4, 6, 8, 10, and 15 min. The blood samples were
putinto 1 mlofdistilled waterand radioassayed. At
the end of 60 min, the mice were sacrificed by
decapitation and drained ofblood. Theliver, spleen,
lungs, thymus, andkidneys wereremoved, weighed,
and placed in tubes for counting in a gamma
counter. Blood clearance is expressed as the phago-
cytic index, which is determined by the slope ofthe
clearance curve. Organ distribution is expressed as
percent organ uptake and cpm/mg tissue (specific
activity).
In orderto determine whetherornottolerance to
certain halomethanes could be induced, the follow-
ing experiment was conducted. Groups ofmale and
female mice were gavaged with trichloromethane
at the doses previously stated for 90 days. They
were then given a single gavaged dose of 1000
mg/kg, an amount approximating the LD50 dose,
and observed for lethality.
If a one-way analysis of variance of the means
showed treatment effects, a Dunnett's T-test was
performed (12). Values which differ from vehicle
control at p < 0.05 are noted in the tables. Each of




CD-1 male and female mice were given trichlo-
romethane, bromodichloromethane, dibromochloro-
*methane and tribromomethane bygavage at 50, 125
or250mg/kg/day for 14days. Nochemicallyinduced
deaths were noted with any of the compounds. At
the end ofthis period the animals were necropsied.
Table 1 lists all the parameters observed in the
subchronic 14- and 90-day studies. The data pre-MUNSON ET AL.
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Enumeration of antibody-forming cells
Hemagglutination
Table 2. Effects oftrichloromethane upon CD-1 male mice following 14 days of exposure by gavage.
Parameter Vehicle (12)' 50 mg/kg (8)a 125 mg/kg (8)a 250 mg/kg (7)a
Body weights, g 31.3 ± 0.5 29.6 ± 0.5 31.2 ± 0.5 26.3 ± 1.2b
Organ weights
Liver, mg 1632 ± 48 1734 ± 34 2031 ± 63b 2111 ± 126b
(% body weight) (5.22) (5.87) (6.50)b (8.01)b
Spleen, mg 141 ± 8 178 + 7b 149 ± 13 110 ± 6
(% body weight) (0.45) (0.60)b (0.40) (0.42)
Clinical chemistry
SGPT, IU/1. 60 ± 9 81 ± 12 95 ± 22 2163 ± 27"
Humoral immunity
AFC/spleen x 105 2.89 ± 0.28 1.44 ± 0.18" 1.35 ± 0.24" 1.02 ± 0.12"
AFC/10' cells 3253 ± 171 2057 ± 152" 1700 ± 190b 1405 ± 101"
Hemagglutination (log2 titer) 7.74 ± 0.23 7.82 ± 0.27 7.32 ± 0.19 7.32 ± 0.22
aNumber of mice per group given in parentheses following each dose level.
bSignificant at p < 0.05 level, Dunnett's T-test.
sented inthismanuscriptrepresents alteration which
occurred in a dose-dependent fashion or at the
total AFC and at the intermediate and high doses
when expressed as AFC/106 spleen cells; however,
trends are omitted in an effort to minimize presen-
tation of data.
Trichloromethane. Males exposed to the high
dose oftrichloromethane showed a decrease inbody
weight (Table 2). Liver weights were increased at
125 and 250 mg/kg regardless ofthe method ofdata
expression. Spleenweight was significantly elevated
at the low dose alone. SGPT was increased in the
high dose group. The most striking change occur-
ring in the males was a decrease in AFC expressed
as total number and per 106 spleen cells at all levels
oftreatment. Hemagglutination titer was not signi-
ficantly affected, nor were any alterations in cell-
mediated immunity observed.
No significant change in body weight was seen in
the female mice (Table 3). Liver weights were
increased at all dose levels when the results were
expressed as percent ofbody weight and in thehigh
doseregardless ofthe method ofexpression. Spleen
weights showed a decreasing trend with increasing
dose weight levels but did not attain significance at
the p < 0.05 level. Changes in clinical chemistry
parameters included increased SGOT and SGPT
values at the high dose and a decrease in serum
glucose attheintermediate and highdoses. Humoral
immunity was depressed at all doses in terms of
highest dose level only. Parameters which were
essentially unchanged or did not reveal relevant
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Table 3. Effects of trichloromethane upon CD-1 female mice following 14 days of exposure by gavage.
Parameter Vehicle (12)' 50 mg/kg (12)1 125 mg/kg (8)a 250 mg/kg (12)'
Body weights, g 26.3 ± 0.6 25.0 ± 0.6 25.2 ± 0.6 25.6 ± 0.8
Organ weights
Liver, mg 1442 ± 44 1518 ± 27 1517 ± 57 1786 ± 52
(% body weight) (5.49) (6.08)b (6.03)b (6.99)b
Spleen, mg 151 ± 9 138 ± 8 140 ± 14 134 ± 6
(% body weight) (0.57) (0.56) (0.55) (0.52)
Clinical chemistry
SGPT, IU/1. 53 ± 5 47 ± 4 58 ± 4 154 ± 30b
SGOT, IU/1. 97 ± 7 78 ± 5 76 ± 4 143 ± 15b
Glucose, mg-% 133 ± 4 136 ± 3 114 ± 4b 83 ± 6b
Humoral immunity
AFC/spleen x 105 1.35 ± 0.3 0.89 ± 0.05b 0.58 ± 0.6b 0.41 ± 0.05b
AFC/10' cells 1692 ± 67 1661 ± 84 1157 ± 87 1253 ± 76
Hemagglutination (log2 titer) 8.07 ± 0.22 7.70 ± 0.18 7.82 ± 0.19 7.40 ± 0.26
aNumber ofmice per group given in parentheses following each dose level.
bSignificant at p < 0.05 level, Dunnett's T-test.
Table 4. Effects of bromodichloromethane upon CD-1 male mice following 14 days of exposure by gavage.
Parameter Vehicle (12)^ 50 mg/kg (8)a 125 mg/kg (8)a 250 mg/kg (9)'
Body weights, g 32.9 ± 0.6 33.2 ± 0.6 31.1 ± 1.0 25.8 ± 1.2b
Organ weights
Liver, mg 1904 ± 65 2050 ± 72 2083 ± 115 2851 ± 79
(% body weight) (5.78) (6.17) (6.70)b (7.21)b
Spleen, mg 160 ± 12 143 ± 6 136 ± 10 99
± llb
(% body weight) (0.49) (0.43) (0.44) (0.38)
Hematology
Fibrinogen (mg %) 320 ± 14 345 ± 15 283 ± 10 276 ± 17b
Clinical chemistry
Glucose, mg-% 179 ± 6 197 ± 9 186 ± 16 124 ± 11b
SGOT, IU/1. 70 ± 10 159 ± 28 172 ± 19 643 ± 125
SGPT, IU/1. 35 ± 2 91 ± 17 118 ± 29 703 ± 12b
BUN, mg-% 23 ± 1 24 ± 2 28 ± 4 47 + 4
Humoral immunity
AFC/spleen x 105 1.36 ± 0.12 0.96 ± 0.14 0.98 ± 0.13 0.66 ± 0.11b
AFC/106 cells 1196 ± 85 961 ± 60 1000 ± 78 1024 ± 72
Hemagglutination (log2 titer) 9.50 ± 0.18 9.20 ± 0.13 8.95 ± 0.18b 8.77 ± 0.24b
aNumber ofmice per group given in parentheses following each dose level.
bSignificant at p < 0.05 level, Dunnett's T-test.
hemagglutination titer was not significantly affect-
ed.
Bromodichloromethane. A decrease in body
weight was seen in the high dose group of male
mice after 14 days ofbromodichloromethane admini-
stration (Table 4). Liver weights were increased at
the intermediate and high dose levels when the
data were expressed as percent of body weight.
The decrease in spleen weight was significant only
atthehigh dose, but anonsignificant decrease could
be observed at all dose levels. A decrease in the
fibrinogen level at 250 mg/kg was seen. Clinical
chemistry changes occurred only in the high dose
groupandincludedadecreaseinglucoseandincreases
in SGOT, SGPT and BUN. The immune system
was affected as evidenced by decreases in AFC/
spleen and hemagglutination titer, both in the high
dose group animals.
Female mice in the high dose group showed a
significant reduction in body weight (Table 5). An
increase in liver size was manifest in the intermedi-
ate and high dose groups only when the data were
expressed as percent ofbodyweight. Spleenweight
was decreased at the 125 and 250 mg/kg dosages,
both as total milligrams and as percent of body
weight. Hematological studies revealed a decrease
in fibrinogen levels at the intermediate and high
doseregimens. Changes in clinicalchemistryparam-
eters were observed in the high dose group and
includedelevationsinSGOT, SGPT, andBUN serum
levels. The humoral immunity alterations seen as a
resultofbromodichloromethane administration were
decreasesinAFC/spleenandhemagglutinationtiter,
observed inthe intermediate andhigh dose groups.
Dibromochloromethane. Fourteen-dayadmini-
stration of dibromochloromethane caused a reduc-
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Table 5. Effects of bromodichloromethane upon CD
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-1 female mice following 14 days of exposure by gavage.
Parameter Vehicle (12)' 50 mg/kg (8)a 125 mg/kg (8)a 250 mg/kg (11)'
Body weights, g 26.6 ± 0.4 26.0 ± 0.6 24.9 ± 0.6 21.5 ± 1.0b
Organ weights
Liver, mg 1432 ± 46 1584 ± 73 1608 ± 59 1553 ± 58
(% body weight) (5.36) (6.08) (6.46)b (7.31)b
Spleen, mg 162 ± 7 136 ± 11 112 ± 7b 82±10b
(% body weight) (0.61) (0.52) (0.45)b (0.37)b
Hematology
Fibrinogen (mg %) 226 ± 8 209 ± 7 191 ± 12" 119 ± 11b
Clinical chemistry
SGPT, IUI1. 50 ± 7 49 ± 3 184 ± 40 648 ± 73"
SGOT, IU/1. 94 ± 10 85 ± 7 215 ± 38 774 ± 51b
BUN, mg-% 29 ± 1 28 ± 2 31 ± 2 41 ± 2b
Humoral immunity
AFC/spleen x 105 1.11 ± 0.10 1.19 ± 0.15 0.55 ± 0*08b 0.35 ± 0.05"
AFC/106 cells 1018 ± 73 1133 ± 61 791 ± 61 801 ± 69
Hemagglutination (log2 titer) 8.91 ± 0.15 9.18 ± 0.14 8.32 ± 0.27 7.91 ± 0.15
aNumber ofmice per group given in parentheses following each dose level.
bSignificant at p < 0.05 level, Dunnett's T-test.
Table 6. Effects ofdibromochloromethane upon CD-1 male mice following 14 days of exposure by gavage.
Parameter Vehicle (11)' 50 mg/kg (8)a 125 mg/kg (8)a 250 mg/kg (12)'
Body weights, g 32.3 ± 0.7 33.5 ± 1.0 31.7 ± 0.07 25.8 ± 0.8b
Organ weights
Liver, mg 1851 ± 72 2148 ± 101 2376 ± 182 2007 ± 105
(% body weight) (5.72) (6.40) (7.49)b (7.74)b
Spleen, mg 162 ± 7 154 ± 10 145 ± 8 96 ± 8b
(% body weight) (0.50) (0.46) (0.46) (0.37)b
Hematology
Fibrinogen (mg %) 309 ± 10 310 ± 5 296 ± 8 251 ± 15"
Clinical chemistry
Glucose, mg-% 274 ± 14 289 ± 14 252 ± 12 151 ± 8b SGPT, IU/1. 48.6 ± 5.8 68.4 ± 7.9 83.5 ± 11.1 486.1 ± 61.9"
SGOT, IU/l. 97.9 ± 10.8 101.9 ± 10.3 102.8 ± 11.1 474.6 ± 67.5b
Humoral immunity
AFC/spleen x 105 1.50 ± 0.16 1.39 ± 0.13 1.01 ± 0.28 0.74 ± 0.16"
AFC/10' cells 1611 ± 115 1484 ± 165 1114 ± 191" 1088 ± 105"
Hemagglutination (log2 titer) 9.41 ± 0.08 9.57 ± 0.16 9.32 ± 0.00 8.82 ± 0.26b
Cell-mediated immunity
Popliteal lymph node 11.06 ± 0.95 8.33 ± 1.85 8.27 ± 1.12 4.30 ± 0.93b
(Stimulation Index)
aNumber ofmice per group given in parentheses following each dose level.
bSignificant at p < 0.05 level, Dunnett's T-test.
tion in body weight in the males at the high dose
(Table 6). Liver weights were increased at 125 and
250 mg/kg/day when expressed as percent of body
weight. Spleen and thymus values decreased signifi-
cantly at the high dose whether the data was
expressed as total milligrams or as percent ofbody
weight. Of the hematological parameters, only
fibrinogen was affected, with a decrease occurring
at the high dose. Clinical chemistry alterations
were increases in SGPT and SGOT and a decrease
in serum glucose, all in the high dose group. Both
humoral and cell-mediated immunity were affected
by dibromochloromethane. The number of AFC
was significantly reduced when expressed as total
cells or as AFC/106 spleen cells. This was noted at
the high dose, as was a reduction in hemagglutina-
tion titer. Cell-mediated immunity, as measured by
the popliteal lymph node stimulation index, was
depressed at the high dose. It should be noted that
even though the changes were significant only at
the 250 mg/kg/day level, the decreasing trend can
be observed with the lower'doses.
No significant body weight change was observed
in females receiving dibromochloromethane. The
major organ weight change in the females was an
increase in liver size in the intermediate and high
dose groups (Table 7). The ability of the liver to
metabolize hexobarbital was impaired at the inter-TOXICOLOGY OF DRINKING WATER CONTAMINANTS
Table 7. Effects of dibromochloromethane upon CD-1 female mice following 14 days of exposure by gavage.
Parameter Vehicle (12)a 50 mg/kg (8)a 125 mg/kg (8)a 250 mg/kg (12)a
Body weights, g 29.9 ± 0.5 27.1 ± 0.7 26.1 ± 0.9 26.3 ± 0.7
Organ weights
Liver, mg 1528 ± 56 1622 ± 61 1735 ± 93 1923 ± 62
(% body weight) (5.67) (5.98) (6.63)b (7.33)b
Hematology
Fibrinogen (mg %) 260 ± 6 259 ± 6 248 ± 10 233 ± 7
Clinical chemistry
Glucose, mg-% 157 ± 4 148 ± 10 160 ± 8 105 ± 17b
SGPT, IU/l. 54 ± 6 73 ± 14 107 ± 16 449 ± 44b
SGOT, IU/I. 112 ± 8 124 ± 17 156 ± 17 526 ± 53b
Hexobarbital sleeping time, minc 15.1 ± 0.9 17.3 ± 1.4 27.7 ± 1.9b 37.4 ± 2.5b
Humoral immunity
AFC/spleen x 105 1.34 ± 0.11 1.00 ± 0.12 0.79 ± 0.19 0.45 ± 0.07
AFC/10' cells 1641 ± 85 1418 ± 80 1071 ± 195 1013 ±
Hemagglutination (log2 titer) 9.49 ± 0.17 9.70 ± 0.18 9.20 ± 0.30 8.82± 0.15b
aNumber of mice per group given in parentheses following each dose level.
bSignificant at p < 0.05 level, Dunnett's T-test.
cInduced by 80 mg/kg hexobarbital.
Table 8. Effects of tribromomethane upon CD-1 male mice following 14 days of exposure by gavage.
Parameter Vehicle (10)a 50 mg/kg (7)' 125 mg/kg (7)a 250 mg/kg (10)a
Body weights, g 23.0 ± 0.9 24.5 ± 0.8 26.1 ± 0.3b 25.8 ± 0.52b
Organ weights
Liver, mg 1337 ± 68 1485 ± 65 1682 ± 28 1779 ± 63b
(% body weight) (5.79) (6.06) (6.44)b (6.90)b
Hematology
Fibrinogen (mg %) 302 ± 24 283 ± 34 274 ± 16 218 ± 17
Prothrombin time, sec 7.4 ± 0.1 6.8 ± 0.2b 7.0 ± O.lb 6.8 ± 0.2b
Clinical chemistry
Glucose, mg-% 233 ± 9 223 ± 11 204 ± 12 195 ± 8b
SGOT, IU/l. 92 ± 6 110+ 19 80 ± 8 159 ± 33
BUN, mg-% 36 ± 1 36 ± 1 34 ± 1 31 + lb
Humoral immunity
AFC/spleen x 105 6.07 ± 0.6 5.95 ± 0.6 6.69 ± 1.1 3.44 ± 0.5
AFC/106 cells 1310 ± 75 1279 ± 99 1368 ± 52 936 ± 79b
Cell-mediated immunity
Delayed type hypersensitivity 3.97 ± 0.53 2.22 ± 0.26 4.11 ± 1.21 1.96 ± 0.48
(Stimulation Index)
aNumber of mice per group given in parentheses following each dose level.
bSignificant at p < 0.05 level, Dunnett's T-test.
mediate and high dose as evidenced by increased
hexobarbital sleeping times. The only hematologi-
cal change was a slight decrease in fibrinogen atthe
high dose. Altered clinical chemistry parameters
were increases in SGPT and SGOT and a decrease
in serum glucose, all occurring at 250 mg/kg/day. A
decrease in AFC/spleen and AFC/106 spleen cells
wasnotedintheintermediate and highdose groups,
whereas a reduction of hemagglutination titer oc-
curred only at the high dose.
Tribromomethane. Tribromomethanecausedan
increase in body weight in the intermediate and
high dose groups of the males (Table 8). Liver
weight, expressed as total milligrams or percent of
body weight, increased at the 125 and 250 mg/kg
dosages. Spleen weight was unchanged. Hemato-
logical changes included a decrease in fibrinogen at
the highest dose and a reduction in prothrombin
time occurring at all dosages. Clinical chemistry
changes all appeared at the 250 mg/kg level and
included a decrease in serum glucose and BUN and
an increase in SGOT. Both humoral and cellular
immunity were depressed in the high dose group.
Thechangeinhumoralimmunitywasevidentwhether
expressed as AFC/spleen or AFC/106 cells.
In contrast to the males' change in body weight,
females showed a significant decrease at the high
dose (Table 9). An increase in liver weight was
evident at the high doseregardless ofthe method of
expression, whereas the decrease in spleen weight
was significant only when expressed as total milli-
grams and occurred at the intermediate and high
123Table 9. Effects of tribromomethane upon CD-1 female mice following 14 days of exposure by gavage.
Parameter Vehicle (12)' 50 mg/kg (7)a 125 mg/kg (6)a 250 mg/kg (7)a
Body weights, g 22.3 t 0.6 20.4 t 0.5 20.6 t 0.5 19.5 ± 0.9"
Organ weights
Liver, mg 1253 t 48 1298 t 47 1248 t 46 1524 t 69b
(% body weight) (5.61) (6.37) (6.07) (7.88)b
Spleen,mg 119 ± 9 99 + 11 89 ± 53 ±5b
(% body weight) (0.53) (0.48) (0.46) (0.27)
Clinical chemistry
SGOT, IU/1. 80.4 ± 6.2 75.5 + 8.6 65.8 + 13.5 129.7 ± 17.2b
aNumber of mice per group given in parentheses following each dose level.
bSignificant at p < 0.05 level, Dunnett's T-test.
Table 10. Effects of trichloromethane upon CD-1 male mice following 90 days of exposure by gavage.
Parameter Vehicle (11)' 50 mg/kg (8)a 125 mg/kg (7)a 250 mg/kg (12)'
Body weights, g 36.1 ± 0.9 35.5 ± 0.8 34.1 ± 1.3 36.3 ± 0.8
Organ weights
Liver, mg 1921 ± 69 2020 ± 70 2025 ± 130 2428 ± 115b
(% body weight) (5.31) (5.69) (5.91) (6.65)b
Spleen, mg 156 ± 13 139 ± 12 141 ± 12 180 ± 9
(% body weight) (0.43) (0.39) (0.41) (0.44)
Clinical chemistry
Glucose, mg-% 225 ± 11 265 ± 9 286 ± 13 318 ± 15b
SGPT, IU/1. 63 ± 4 58 6 76 ± 6 81 ± 6
SGOT, IU/1. 90 ± 8 105 12 106 ± 14 131 21
Humoral immunity
AFC/spleen x 105 2.27 ± 0.20 1.50 ± 0.21b 2.41 ± 0.27 1.34 ± 0.18b
AFC/106 cells 1723 ± 91 1371 ± 151 1620 ± 115 1081 ± 105b
Hemagglutination (log2 titer) 9.50 ± 0.18 9.20 ± 0.13 9.32 ± 0.22 9.16 ± 0.17
Hepatic microsomal activities
Microsomal protein, mg/g liver 26.9 ± 0.64 24.4 ± 0.60 26.4 ± 0.69 23.5 ± 1.09b
Glutathione, mmole/g liver 10.0 ± 0.39 10.6 ± 0.36 10.6 ± 0.37 10.1 ± 0.48
Aniline hydroxylase, nmole/mg/min 1.86 ± 0.06 2.22 0.11b 1.81 ± 0.02 1.52 ± 0.06b
Hexobarbital sleeping time (min)c 36.2 ± 4.0 41.8 ± 4.1 46.8 ± 4.6 47.4 ± 4.9
aNumber ofmice per group given in parentheses following each dose level.
bSignificant at p < 0.05 level, Dunnett's T-test.
cInduced by 80 mg/kg hexobarbital.
doses. The only alteration in clinical chemistry val-
ues was an increase in SGOT, which occurred in the
250 mg/kg group. The immune system was not
affected by tribromomethane as measured by the
humoral and cell mediated responses to sRBC.
Subchronic Ninety-Day Study
CD-1 male and female mice were gavaged with
trichloromethane at 50, 125 or 250 mg/kg/day for 90
days. No chemically induced deaths were attrib-
uted to the compound during treatment.
Male mice showed no significant changes in body
weight due to treatment (Table 10). Liver weight
was increased both as total milligrams and as per-
cent ofbody weight at the high dose. Spleen weight
was not affected. Clinical chemistry values were
essentially normal except for serum glucose, which
was elevated at the intermediate and high doses.
Humoral immunity was affected at the 250 mg/kg
dose in that AFC/spleen and AFC/106 cells were
decreased. Total AFC/spleen also decreased at the
low dose. Hemagglutination titer was not affected.
Hepatic microsomal activities were evaluated in
the 90-day exposure study. Table 10 shows a sup-
pression of microsomal protein at the high dose.
There were also changes in the microsomal enzyme
anilinehydroxylase, butthey werenotdose-related,
increasing at the low dose and decreasing at the
high dose.
Ninety-day trichloromethane administration did
not alter body weights at any level of treatment in
the female mice (Table 11). Liver weights were
increased at all levels oftreatment when expressed
either as total milligrams or as percent of body
weight. Serum glucose was increased in the females
at the high dose only. The only change occurring in
humoralimmunity was adecrease inAFC/106spleen
cells at the low dose; not a dose-related effect. A
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Table 11. Effects of trichloromethane upon CD-1 female mice following 90 days of exposure by gavage.
Parameter Vehicle (12)' 50 mg/kg (7)a 125 mg/kg (7)a 250 mg/kg (12)'
Body weights, g 28.6 ± 0.5 29.2 ± 1.1 30.6 ± 0.5 30.8 ± 0.9
Organ weights
Liver, mg 1293 ± 47 1606 ± 6 1835 ± 42 1991 ± 66
(% body weight) (4.51) (5.54)b (5.99)b (6.48)
Spleen, mg 168 ± 12 158 ± 14 187 ± 25 161 ± 8
(% body weight) (0.59) (0.55) (0.62) (0.52)
Clinical chemistry
Glucose, mg-% 232 ± 6 248 ± 15 261 ± 16 295 ± 9b
Humoral immunity
AFC/spleen x 105 2.01 ± 0.24 1.56 ± 0.27 1.58 ± 0.14 1.76 ± 0.23
AFC/106 cells 1324 ± 63 984 ± 59b 1191 ± 79 1086 ± 79
Hemagglutination (log2 titer) 9.74 ± 0.19 9.66 ± 0.21 9.32 ± 0.22 9.66 ± 0.19
Cell-mediated immunity
Delayed type hypersensitivity 4.12 ± 0.56 3.14 ± 0.41 3.39 ± 0.57 2.48 ± 0.3
(Stimulation Index)
Hepatic microsomal activities
Microsomal protein, mg/g liver 28.0 ± 0.79 24.9 ± 0.84 22.9 ± 1.11b 22.3 ± 1.03b
Glutathione, mmole/g liver 6.91 ± 0.24 9.99 ± 0.47b 10.79 ± 0.50b 11.20 ± 0.51b
Aniline hydroxylase, nmole/mg/min 1.48 ± 0.04 1.41 ± 0.08 1.11 ± 0.06 1.09 ± 0.06
Hexobarbital sleeping time (min)c 19.2 ± 2.3 34.0 ± 2.9 35.0 ± 1.8b 46.5 ± 4.4b
aNumber of mice per group given in parentheses following each dose level.
bSignificant at p < 0.05 level, Dunnett's T-test.
cInduced by 80 mg/kg hexobarbital.
Table 12. Hyporesponsiveness to lethal effects oftrichloromethane.a
Females Males
Group Survivors/N % Mortality Survivors/N % Mortality
Vehicle 7/11 36 1/9 89
50 mg/kg 8/8 0 5/9 44
125 mg/kg 8/8 0 5/6 17
250 mg/kg 7/7 0 7/8 13
aAnimals were given a single gavage of 1000 mg/kg after 90 days of exposure to the doses listed.
decrease was noted in the cell-mediated delayed
type hypersensitivity assay, occurring in the high
dose group.
Thekidneys, livers and spleensofmaleandfemale
micegavaged with vehicle did not exhibithistopatho-
logicalchanges. Histologicexaminationoftheselected
organs of mice gavaged with chloroform revealed
normal spleens; however, slight histopathologic
changes were seen in the kidneys and livers ofboth
males and females. The kidneys exhibited small
intertubularcollectionsofchronicinflammatorycells,
mainly lymphocytes. The liver exhibited general-
ized hydropic degeneration ofhepatocytes and occa-
sional small focal collections oflymphocytes. Small
amountsofextravasatedbilewereoccasionallynoticed
in the females. Most of this extravasated material
was present within sinusoicial Kupffer cells.
The females displayed a slight decrease in micro-
somal protein at the intermediate and high doses
(Table 11). Anilinehydroxylaseactivityalsodecreased
at these doses. Glutathione increased at all three
levels of treatment, a change not observed in the
males.
Tolerance Study
As shown in Table 12, a degree of protection to
the lethal effects of trichloromethane was induced
bysubchronic90-dayexposure. Asingle 1000mg/kg
dose was lethal to 36% of the females who had
received vehicle for 90 days but none ofthe treated
mice died. Mortality of vehicle-treated males was
89%, while in the trichloromethane-treated groups,
13-44% died.
Discussion
A result of industrialization and urban develop-
ment has been an increased need for a monitoring
system to assess environmental contamination per-
taining to air, food, and water supplies. Since it is
impractical, if not impossible, to completely elimi-
nate many low-level contaminants, it is imperative
that we understand the effects ofexposure to these
contaminants. Our efforts to insure potable water
supplies through chemical treatment have contrib-
uted to the ever-increasing number of compounds
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to which we are exposed. The purpose ofthis study
was to examine the effects oflow-level exposure to
selected halomethanes which are found in finished
water supplies as a result of chlorination or indus-
trial wastes. In addition to standard toxicological
evaluation, the main intent was to investigate the
effects ofthese chemicals upon the immune system.
The use of the random-bred CD-1 mouse was a
compromise between the random-bred rat, which is
usedforconventionaltoxicitytesting, andtheinbred
mouse, which is most suitable for studies involving
immune system function. Gavage was selected as
the route ofadministration to control the amount of
chemical to which the animals were exposed.
The majoreffect seen in subchronic 14-day admini-
strationofthecompounds inregard toorganweights
was an increase in liver weight. This was evident
for all compounds and usually occurred in the inter-
mediate and high dose groups of both sexes. This
effect seemed to carry overinto the 90-day study as
was more evident in the female groups, in which
liver weight was increased at all doses, whereas a
significant change was only seen at the high dose in
the males. It should be noted that in a number of
instances the spleen weight decreased. This is of
importance since the spleen is intimately involved
with immune system function.
Hematological studies did not reveal any major
changes in the cellular components of this system.
However, a decrease in fibrinogen levels was noted
with dibromochloromethane, tribromomethane and
bromodichloromethane administration. This may
reflect decreased capacity ofthe liver to synthesize
the protein.
Alterations which occurred in the clinical chemis-
try parameters were indicative of hepatic distur-
bances. SGPT or SGOT were increased in both
sexeswithallcompoundsadministeredinthe 14-day
studies. In the 90-day study, this effect was not
seen, perhaps indicative ofrecovery or tolerance to
the compound used in the long-term experiment.
Theelevationinserumglucoselevelinthesubchronic
90-day exposure may also reflect alteration in the
ability of the liver to control glucose levels.
Although cell-mediated immunity was depressed
in a few instances, these changes occurred only
with the highest dose. Suppression of the humoral
immune system was observed with all the chemi-
cals under investigation in both sexes, the only
exception being the females receiving tribromo-
methane for 14 days. Furthermore, adose response
was 'evident in almost all instances and, even when
the decreases were not statistically significant, a
definite trend toward reduction could be noticed.
Thus it appears that the humoral immune system
may be an indicator of halomethane toxicity. Fur-
ther studies involving functional aspects of immu-
nity are necessary to strengthen this observation.
The observation that subchronic 90-day exposure
to trichloromethane did not exacerbate the changes
seen to occur as a result of14-day administration of
the compound and, in fact, were less severe, points
out the need for short-term studies toreveal effects
which although transient, may have serious conse-
quences under given circumstances, e.g., exposure
topathogens whiletheimmune systemis depressed.
This is supported by the tolerance experiment,
which revealed compensatory mechanisms being
activated during subehronic 90-day exposure.
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